Samir Dervisevic

ORCID: 0000-0003-0633-8611
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • SARS-CoV-2 and COVID-19 Research
  • COVID-19 Clinical Research Studies
  • SARS-CoV-2 detection and testing
  • Animal Virus Infections Studies
  • Long-Term Effects of COVID-19
  • Hepatitis C virus research
  • COVID-19 epidemiological studies
  • Hepatitis B Virus Studies
  • Respiratory viral infections research
  • Viral Infections and Outbreaks Research
  • COVID-19 and healthcare impacts
  • Bacteriophages and microbial interactions
  • Viral gastroenteritis research and epidemiology
  • Liver Disease Diagnosis and Treatment
  • Plant Virus Research Studies
  • COVID-19 and Mental Health
  • Disaster Response and Management
  • Disaster Management and Resilience
  • Respiratory Support and Mechanisms
  • Antibiotic Use and Resistance
  • Genomics and Phylogenetic Studies
  • Nosocomial Infections in ICU
  • Sepsis Diagnosis and Treatment
  • COVID-19 Impact on Reproduction
  • Viral-associated cancers and disorders

Norfolk and Norwich University Hospital
2014-2024

Norwich Research Park
2021-2024

International Severe Acute Respiratory and Emerging Infection Consortium
2023

St Mary's Hospital
2023

Norfolk and Norwich University Hospitals NHS Foundation Trust
2015-2022

The Queen's Medical Research Institute
2022

University of East Anglia
2016-2022

Centre for Inflammation Research
2022

University of Edinburgh
2022

Roslin Institute
2022

We present CoronaHiT, a platform and throughput flexible method for sequencing SARS-CoV-2 genomes (≤ 96 on MinION or > Illumina NextSeq) depending changing requirements experienced during the pandemic. CoronaHiT uses transposase-based library preparation of ARTIC PCR products. Method performance was demonstrated by 2 plates containing 95 59 nanopore platforms comparing to LoCost method. Of 154 samples sequenced using all 3 methods, ≥ 90% genome coverage obtained 64.3% LoCost, 71.4%...

10.1186/s13073-021-00839-5 article EN cc-by Genome Medicine 2021-02-09

In the initial stages of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) COVID-19 pandemic, a plethora new serology tests were developed and introduced to global market. Many not evaluated rigorously, there is significant lack concordance in results across methods. To enable meaningful clinical decisions be made, robustly evaluated, quantitative methods are needed. These should harmonized primary reference material, allowing for comparison trial data improved decision making. A...

10.1128/jcm.00288-21 article EN cc-by Journal of Clinical Microbiology 2021-07-14

The COVID-19 pandemic has spread rapidly throughout the world. In UK, initial peak was in April 2020; county of Norfolk (UK) and surrounding areas, which a stable, low-density population, over 3200 cases were reported between March August 2020. As part activities national Genomics Consortium (COG-UK) we undertook whole genome sequencing SARS-CoV-2 genomes present positive clinical samples from region. These collected by four major hospitals, multiple minor care facilities community...

10.1099/mgen.0.000589 article EN cc-by Microbial Genomics 2021-03-24

Abstract It has been proposed that occult hepatitis B virus (HBV) infection, defined as detectable HBV‐DNA in serum with undetectable surface antigen (HBsAg − ), is associated raised transaminases HIV‐infected persons. The aim of this study was to determine the prevalence HBV infection two independent cohorts, and investigate its predictors, association alanine‐aminotransferase (ALT) levels response antiretroviral therapy. Sera from HBsAg persons core antibody (anti‐HBc + ) were tested by...

10.1002/jmv.20954 article EN Journal of Medical Virology 2007-08-17

Abstract Adefovir dipivoxil has been used alone or together with lamivudine to suppress lamivudine‐resistant hepatitis B virus (HBV). However, the dynamics of HBV populations under different selection pressures and their impact on treatment outcome are poorly understood. Pyrosequencing® was applied quantify longitudinally evolution wild type lamivudine/ adefovir‐resistant HBV. Eight patients, HBV, were randomized receive adefovir monotherapy adefovir/lamivudine combination therapy for a...

10.1002/jmv.21206 article EN Journal of Medical Virology 2008-05-06

The emergence of variants SARS-CoV-2 has created challenges for the testing infrastructure. Although large-scale genome sequencing facilitated hospital and public health responses, access to facilities globally is variable turnaround times can be significant, so there a requirement rapid cost-effective alternatives. Applying polymerase chain reaction (PCR)-based single nucleotide polymorphism (SNP) approach enables (<4 h) identification lineages from nucleic acid extracts, through presence...

10.3390/v13102028 article EN cc-by Viruses 2021-10-08

Objective To assess, within communities experiencing Ebola virus outbreaks, the risks associated with disposal of human waste and to generate recommendations for mitigating such risks.Methods A team expertise in Hazard Analysis Critical Control Points framework identified products from care individuals disease constructed, tested confirmed flow diagrams showing creation products.After listing potential hazards each step diagram, conducted a hazard analysis, determined critical control points...

10.2471/blt.15.163931 article EN cc-by Bulletin of the World Health Organization 2016-03-03

Abstract The COVID-19 pandemic has spread rapidly throughout the world. In UK, initial peak was in April 2020; county of Norfolk (UK) and surrounding areas, which a stable, low-density population, over 3,200 cases were reported between March August 2020. As part activities national Genomics Consortium (COG-UK) we undertook whole genome sequencing SARS-CoV-2 genomes present positive clinical samples from region. These collected by four major hospitals, multiple minor care facilities community...

10.1101/2020.09.28.20201475 preprint EN cc-by medRxiv (Cold Spring Harbor Laboratory) 2020-09-30

Abstract The COVID-19 pandemic has spread to almost every country in the world since it started China late 2019. Controlling requires a multifaceted approach including whole genome sequencing support public health interventions at local and national levels. One of most widely used methods for is ARTIC protocol, tiling PCR followed by Oxford Nanopore (ONT) up 96 samples time. There need, however, flexible, platform agnostic, method that can provide multiple throughput options depending on...

10.1101/2020.06.24.162156 preprint EN cc-by bioRxiv (Cold Spring Harbor Laboratory) 2020-06-24

In the emergency of SARS-CoV-2 pandemic, great efforts were made to quickly provide serology testing medical community however, these methods have been introduced into clinical practice without complete validation usually required by regulatory organizations. patient samples (n = 43) analyzed alongside pre-pandemic control specimen 50), confirmed respiratory infections inflammatory polyarthritis 22) and positive for thyroid stimulating immunoglobulin 30). Imprecision, diagnostic sensitivity...

10.1371/journal.pone.0245914 article EN cc-by PLoS ONE 2021-02-17

This study examines the utility of resistance testing during treatment interruption, making comparisons with current IAS guidelines. A total 188/1279 tests (14%) were performed interruption; 69/188 (36.7%) demonstrated key mutations. Time off therapy and number previous drugs both significantly associated presence We conclude that is value up to 3 months after may convey some benefit 12 months.

10.1097/01.aids.0000194807.81917.50 article EN AIDS 2005-11-10

Abstract In the United Kingdom, National Screening Programme for identification of hepatitits B virus (HBV) infection in pregnant women uses HBV e antigen (HBeAg) and antibody to HBeAg (anti-HBe) as markers infectivity determine use immunoglobulin hepatitis B. Serum samples from 114 HBV-infected were analyzed. Viral loads correlated with HBeAg/anti-HBe status viral genotypes. Among 95 mothers whose serum contained anti-HBe, ranged between undetectable 8.6 × 106 IU/mL (median 228 IU/mL). Ten...

10.3201/eid1311.070578 article EN cc-by Emerging infectious diseases 2007-11-01

Abstract We evaluated the FDA approved SARS-CoV-2 immunoassay (developed at Mount Sinai, by Krammer and colleagues) for identification of COVID-19 seroconversion potential cross-reactivity assay in a United Kingdom (UK) National Health Service (NHS) hospital setting. In our ‘set up’ cohort we found that IgG was detectable 100% patients tested 14 days post positive nucleic acid test. Serum samples taken from pregnant women 2018 were used as negative control group with zero false positives....

10.1101/2020.06.11.20128306 preprint EN medRxiv (Cold Spring Harbor Laboratory) 2020-06-12

DNA assays for viral load (VL) monitoring are key tools in the management of immunocompromised patients with cytomegalovirus (CMV) or Epstein-Barr virus (EBV) infection. In this study, analytical and clinical performances NeuMoDx™ CMV EBV Quant Assays were compared artus QS-RGQ Kits a primary hospital testing laboratory. Patient plasma samples previously tested using kits randomly selected by NeuMoDx assays. The Assay Kit limits detection (LoDs) 20.0 IU/mL 69.7 IU/mL, respectively; 33/75...

10.3390/v16050671 article EN cc-by Viruses 2024-04-25

Background: Most approved vaccines utilise a two-dose strategy. To enable larger groups of patients to receive the first dose, UK government increased gap between two doses from three 12 weeks. Here we report on immunogenicity including effect age and vitamin D status these levels over an 8 week-period.Methods: Blood was collected healthcare workers (HCW) receiving their BNT162b2 vaccine dose January February 2021. Antibody production measured, prior weekly for 4 weeks post immunization,...

10.2139/ssrn.3902470 article EN SSRN Electronic Journal 2021-01-01

Abstract The SARS-CoV-2 ARTIC amplicon protocol is the most widely used genome sequencing method for SARS-CoV-2, accounting over 43% of publicly-available sequences. utilises 98 primers to amplify ∼400bp fragments covering all 30,000 bases. Understanding analytical performance metrics this will improve how data and interpreted. Different concentrations control material were establish limit detection (LoD) protocol. Results demonstrated LoD was a minimum 25-50 virus particles per mL....

10.1101/2021.10.09.21264695 preprint EN cc-by medRxiv (Cold Spring Harbor Laboratory) 2021-10-11

<h3>Background/introduction</h3> Recent national guidance for the detection of gonorrhoea (GC) has raised concerns that majority initial positive GC test results are likely to be false positives when a low prevalence population is screened using nucleic acid amplification (NAAT). Our local chlamydia screening programme uses dual NAAT and reactive rate &lt;1%. All cases referred GUM further investigation. <h3>Aim(s)/objectives</h3> To determine whether from our were true infections or cases....

10.1136/sextrans-2015-052126.53 article EN Sexually Transmitted Infections 2015-05-18
Coming Soon ...